Review





Similar Products

resolution omics sequencing stereo seq  (Complete Genomics Inc)
97
Complete Genomics Inc resolution omics sequencing stereo seq
Spatial <t>omics</t> driven characterisation of the TME evolution. (a) , Performing spatial multiomics on tumor samples collected from different stages of cancer development (normal, pre‐malignant, and malignant tissues) enables the characterisation of the spatial landscape associated with tumor progression. This will reveal stage‐specific changes in the spatial architecture of the tumor and will aid in the identification of potential targets to prevent the lesion from becoming malignant. (b) Decoding the spatial biology behind therapeutic response by using spatially resolved technologies reveals the region‐specific ligand‐receptor interactions driving therapeutic response and the cellular architecture that correlates with response. A few examples of spatial correlates of therapeutic response are given. Tumors sensitive to ICB are often associated with the presence of TLS, increased TILs, with elevation of T cell populations such as TCF7 + CD8 + T cells and GZMB + CD8 + T cells. An oncofetal niche consisting of POSTN + CAFs, FOLR2 + TAMs and PLVAP + endothelial cells has been identified to be associated with better response to combination immunotherapy in HCC. The spatial analysis of ICB resistant tumors from multiple cancer types has identified CAF subtypes forming physical barriers, which prevent the infiltration of immune cells into the tumor. ICB, immune checkpoint blockade, TLS, Tertiary Lymphoid Structure, TILs, Tumor‐infiltrating lymphocytes.
Resolution Omics Sequencing Stereo Seq, supplied by Complete Genomics Inc, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/resolution omics sequencing stereo seq/product/Complete Genomics Inc
Average 97 stars, based on 1 article reviews
resolution omics sequencing stereo seq - by Bioz Stars, 2026-05
97/100 stars
  Buy from Supplier
transcriptome sequencing  (Beijing Biomarker Technologies Co Ltd)
86
Beijing Biomarker Technologies Co Ltd transcriptome sequencing
Spatial <t>omics</t> driven characterisation of the TME evolution. (a) , Performing spatial multiomics on tumor samples collected from different stages of cancer development (normal, pre‐malignant, and malignant tissues) enables the characterisation of the spatial landscape associated with tumor progression. This will reveal stage‐specific changes in the spatial architecture of the tumor and will aid in the identification of potential targets to prevent the lesion from becoming malignant. (b) Decoding the spatial biology behind therapeutic response by using spatially resolved technologies reveals the region‐specific ligand‐receptor interactions driving therapeutic response and the cellular architecture that correlates with response. A few examples of spatial correlates of therapeutic response are given. Tumors sensitive to ICB are often associated with the presence of TLS, increased TILs, with elevation of T cell populations such as TCF7 + CD8 + T cells and GZMB + CD8 + T cells. An oncofetal niche consisting of POSTN + CAFs, FOLR2 + TAMs and PLVAP + endothelial cells has been identified to be associated with better response to combination immunotherapy in HCC. The spatial analysis of ICB resistant tumors from multiple cancer types has identified CAF subtypes forming physical barriers, which prevent the infiltration of immune cells into the tumor. ICB, immune checkpoint blockade, TLS, Tertiary Lymphoid Structure, TILs, Tumor‐infiltrating lymphocytes.
Transcriptome Sequencing, supplied by Beijing Biomarker Technologies Co Ltd, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/transcriptome sequencing/product/Beijing Biomarker Technologies Co Ltd
Average 86 stars, based on 1 article reviews
transcriptome sequencing - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
sequences of the entire transcriptome  (Biotechnology Information)
86
Biotechnology Information sequences of the entire transcriptome
Spatial <t>omics</t> driven characterisation of the TME evolution. (a) , Performing spatial multiomics on tumor samples collected from different stages of cancer development (normal, pre‐malignant, and malignant tissues) enables the characterisation of the spatial landscape associated with tumor progression. This will reveal stage‐specific changes in the spatial architecture of the tumor and will aid in the identification of potential targets to prevent the lesion from becoming malignant. (b) Decoding the spatial biology behind therapeutic response by using spatially resolved technologies reveals the region‐specific ligand‐receptor interactions driving therapeutic response and the cellular architecture that correlates with response. A few examples of spatial correlates of therapeutic response are given. Tumors sensitive to ICB are often associated with the presence of TLS, increased TILs, with elevation of T cell populations such as TCF7 + CD8 + T cells and GZMB + CD8 + T cells. An oncofetal niche consisting of POSTN + CAFs, FOLR2 + TAMs and PLVAP + endothelial cells has been identified to be associated with better response to combination immunotherapy in HCC. The spatial analysis of ICB resistant tumors from multiple cancer types has identified CAF subtypes forming physical barriers, which prevent the infiltration of immune cells into the tumor. ICB, immune checkpoint blockade, TLS, Tertiary Lymphoid Structure, TILs, Tumor‐infiltrating lymphocytes.
Sequences Of The Entire Transcriptome, supplied by Biotechnology Information, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sequences of the entire transcriptome/product/Biotechnology Information
Average 86 stars, based on 1 article reviews
sequences of the entire transcriptome - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
transcriptomic sequencing  (Azenta)
86
Azenta transcriptomic sequencing
Spatial <t>omics</t> driven characterisation of the TME evolution. (a) , Performing spatial multiomics on tumor samples collected from different stages of cancer development (normal, pre‐malignant, and malignant tissues) enables the characterisation of the spatial landscape associated with tumor progression. This will reveal stage‐specific changes in the spatial architecture of the tumor and will aid in the identification of potential targets to prevent the lesion from becoming malignant. (b) Decoding the spatial biology behind therapeutic response by using spatially resolved technologies reveals the region‐specific ligand‐receptor interactions driving therapeutic response and the cellular architecture that correlates with response. A few examples of spatial correlates of therapeutic response are given. Tumors sensitive to ICB are often associated with the presence of TLS, increased TILs, with elevation of T cell populations such as TCF7 + CD8 + T cells and GZMB + CD8 + T cells. An oncofetal niche consisting of POSTN + CAFs, FOLR2 + TAMs and PLVAP + endothelial cells has been identified to be associated with better response to combination immunotherapy in HCC. The spatial analysis of ICB resistant tumors from multiple cancer types has identified CAF subtypes forming physical barriers, which prevent the infiltration of immune cells into the tumor. ICB, immune checkpoint blockade, TLS, Tertiary Lymphoid Structure, TILs, Tumor‐infiltrating lymphocytes.
Transcriptomic Sequencing, supplied by Azenta, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/transcriptomic sequencing/product/Azenta
Average 86 stars, based on 1 article reviews
transcriptomic sequencing - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
cngb nucleotide sequence archive  (Complete Genomics Inc)
97
Complete Genomics Inc cngb nucleotide sequence archive
Spatial <t>omics</t> driven characterisation of the TME evolution. (a) , Performing spatial multiomics on tumor samples collected from different stages of cancer development (normal, pre‐malignant, and malignant tissues) enables the characterisation of the spatial landscape associated with tumor progression. This will reveal stage‐specific changes in the spatial architecture of the tumor and will aid in the identification of potential targets to prevent the lesion from becoming malignant. (b) Decoding the spatial biology behind therapeutic response by using spatially resolved technologies reveals the region‐specific ligand‐receptor interactions driving therapeutic response and the cellular architecture that correlates with response. A few examples of spatial correlates of therapeutic response are given. Tumors sensitive to ICB are often associated with the presence of TLS, increased TILs, with elevation of T cell populations such as TCF7 + CD8 + T cells and GZMB + CD8 + T cells. An oncofetal niche consisting of POSTN + CAFs, FOLR2 + TAMs and PLVAP + endothelial cells has been identified to be associated with better response to combination immunotherapy in HCC. The spatial analysis of ICB resistant tumors from multiple cancer types has identified CAF subtypes forming physical barriers, which prevent the infiltration of immune cells into the tumor. ICB, immune checkpoint blockade, TLS, Tertiary Lymphoid Structure, TILs, Tumor‐infiltrating lymphocytes.
Cngb Nucleotide Sequence Archive, supplied by Complete Genomics Inc, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cngb nucleotide sequence archive/product/Complete Genomics Inc
Average 97 stars, based on 1 article reviews
cngb nucleotide sequence archive - by Bioz Stars, 2026-05
97/100 stars
  Buy from Supplier
transcriptome sequencing experiment  (Novogene)
86
Novogene transcriptome sequencing experiment
Spatial <t>omics</t> driven characterisation of the TME evolution. (a) , Performing spatial multiomics on tumor samples collected from different stages of cancer development (normal, pre‐malignant, and malignant tissues) enables the characterisation of the spatial landscape associated with tumor progression. This will reveal stage‐specific changes in the spatial architecture of the tumor and will aid in the identification of potential targets to prevent the lesion from becoming malignant. (b) Decoding the spatial biology behind therapeutic response by using spatially resolved technologies reveals the region‐specific ligand‐receptor interactions driving therapeutic response and the cellular architecture that correlates with response. A few examples of spatial correlates of therapeutic response are given. Tumors sensitive to ICB are often associated with the presence of TLS, increased TILs, with elevation of T cell populations such as TCF7 + CD8 + T cells and GZMB + CD8 + T cells. An oncofetal niche consisting of POSTN + CAFs, FOLR2 + TAMs and PLVAP + endothelial cells has been identified to be associated with better response to combination immunotherapy in HCC. The spatial analysis of ICB resistant tumors from multiple cancer types has identified CAF subtypes forming physical barriers, which prevent the infiltration of immune cells into the tumor. ICB, immune checkpoint blockade, TLS, Tertiary Lymphoid Structure, TILs, Tumor‐infiltrating lymphocytes.
Transcriptome Sequencing Experiment, supplied by Novogene, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/transcriptome sequencing experiment/product/Novogene
Average 86 stars, based on 1 article reviews
transcriptome sequencing experiment - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
transcriptome sequencing  (Novogene)
86
Novogene transcriptome sequencing
Spatial <t>omics</t> driven characterisation of the TME evolution. (a) , Performing spatial multiomics on tumor samples collected from different stages of cancer development (normal, pre‐malignant, and malignant tissues) enables the characterisation of the spatial landscape associated with tumor progression. This will reveal stage‐specific changes in the spatial architecture of the tumor and will aid in the identification of potential targets to prevent the lesion from becoming malignant. (b) Decoding the spatial biology behind therapeutic response by using spatially resolved technologies reveals the region‐specific ligand‐receptor interactions driving therapeutic response and the cellular architecture that correlates with response. A few examples of spatial correlates of therapeutic response are given. Tumors sensitive to ICB are often associated with the presence of TLS, increased TILs, with elevation of T cell populations such as TCF7 + CD8 + T cells and GZMB + CD8 + T cells. An oncofetal niche consisting of POSTN + CAFs, FOLR2 + TAMs and PLVAP + endothelial cells has been identified to be associated with better response to combination immunotherapy in HCC. The spatial analysis of ICB resistant tumors from multiple cancer types has identified CAF subtypes forming physical barriers, which prevent the infiltration of immune cells into the tumor. ICB, immune checkpoint blockade, TLS, Tertiary Lymphoid Structure, TILs, Tumor‐infiltrating lymphocytes.
Transcriptome Sequencing, supplied by Novogene, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/transcriptome sequencing/product/Novogene
Average 86 stars, based on 1 article reviews
transcriptome sequencing - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
transcriptome sequencing  (Hua Da Inc)
86
Hua Da Inc transcriptome sequencing
Spatial <t>omics</t> driven characterisation of the TME evolution. (a) , Performing spatial multiomics on tumor samples collected from different stages of cancer development (normal, pre‐malignant, and malignant tissues) enables the characterisation of the spatial landscape associated with tumor progression. This will reveal stage‐specific changes in the spatial architecture of the tumor and will aid in the identification of potential targets to prevent the lesion from becoming malignant. (b) Decoding the spatial biology behind therapeutic response by using spatially resolved technologies reveals the region‐specific ligand‐receptor interactions driving therapeutic response and the cellular architecture that correlates with response. A few examples of spatial correlates of therapeutic response are given. Tumors sensitive to ICB are often associated with the presence of TLS, increased TILs, with elevation of T cell populations such as TCF7 + CD8 + T cells and GZMB + CD8 + T cells. An oncofetal niche consisting of POSTN + CAFs, FOLR2 + TAMs and PLVAP + endothelial cells has been identified to be associated with better response to combination immunotherapy in HCC. The spatial analysis of ICB resistant tumors from multiple cancer types has identified CAF subtypes forming physical barriers, which prevent the infiltration of immune cells into the tumor. ICB, immune checkpoint blockade, TLS, Tertiary Lymphoid Structure, TILs, Tumor‐infiltrating lymphocytes.
Transcriptome Sequencing, supplied by Hua Da Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/transcriptome sequencing/product/Hua Da Inc
Average 86 stars, based on 1 article reviews
transcriptome sequencing - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
exome capture based transcriptome sequencing rna seq assay  (Twist Bioscience)
86
Twist Bioscience exome capture based transcriptome sequencing rna seq assay
Spatial <t>omics</t> driven characterisation of the TME evolution. (a) , Performing spatial multiomics on tumor samples collected from different stages of cancer development (normal, pre‐malignant, and malignant tissues) enables the characterisation of the spatial landscape associated with tumor progression. This will reveal stage‐specific changes in the spatial architecture of the tumor and will aid in the identification of potential targets to prevent the lesion from becoming malignant. (b) Decoding the spatial biology behind therapeutic response by using spatially resolved technologies reveals the region‐specific ligand‐receptor interactions driving therapeutic response and the cellular architecture that correlates with response. A few examples of spatial correlates of therapeutic response are given. Tumors sensitive to ICB are often associated with the presence of TLS, increased TILs, with elevation of T cell populations such as TCF7 + CD8 + T cells and GZMB + CD8 + T cells. An oncofetal niche consisting of POSTN + CAFs, FOLR2 + TAMs and PLVAP + endothelial cells has been identified to be associated with better response to combination immunotherapy in HCC. The spatial analysis of ICB resistant tumors from multiple cancer types has identified CAF subtypes forming physical barriers, which prevent the infiltration of immune cells into the tumor. ICB, immune checkpoint blockade, TLS, Tertiary Lymphoid Structure, TILs, Tumor‐infiltrating lymphocytes.
Exome Capture Based Transcriptome Sequencing Rna Seq Assay, supplied by Twist Bioscience, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/exome capture based transcriptome sequencing rna seq assay/product/Twist Bioscience
Average 86 stars, based on 1 article reviews
exome capture based transcriptome sequencing rna seq assay - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier

Image Search Results


Spatial omics driven characterisation of the TME evolution. (a) , Performing spatial multiomics on tumor samples collected from different stages of cancer development (normal, pre‐malignant, and malignant tissues) enables the characterisation of the spatial landscape associated with tumor progression. This will reveal stage‐specific changes in the spatial architecture of the tumor and will aid in the identification of potential targets to prevent the lesion from becoming malignant. (b) Decoding the spatial biology behind therapeutic response by using spatially resolved technologies reveals the region‐specific ligand‐receptor interactions driving therapeutic response and the cellular architecture that correlates with response. A few examples of spatial correlates of therapeutic response are given. Tumors sensitive to ICB are often associated with the presence of TLS, increased TILs, with elevation of T cell populations such as TCF7 + CD8 + T cells and GZMB + CD8 + T cells. An oncofetal niche consisting of POSTN + CAFs, FOLR2 + TAMs and PLVAP + endothelial cells has been identified to be associated with better response to combination immunotherapy in HCC. The spatial analysis of ICB resistant tumors from multiple cancer types has identified CAF subtypes forming physical barriers, which prevent the infiltration of immune cells into the tumor. ICB, immune checkpoint blockade, TLS, Tertiary Lymphoid Structure, TILs, Tumor‐infiltrating lymphocytes.

Journal: Clinical & Translational Immunology

Article Title: Spatial omics for profiling the dynamic tumor microenvironment

doi: 10.1002/cti2.70084

Figure Lengend Snippet: Spatial omics driven characterisation of the TME evolution. (a) , Performing spatial multiomics on tumor samples collected from different stages of cancer development (normal, pre‐malignant, and malignant tissues) enables the characterisation of the spatial landscape associated with tumor progression. This will reveal stage‐specific changes in the spatial architecture of the tumor and will aid in the identification of potential targets to prevent the lesion from becoming malignant. (b) Decoding the spatial biology behind therapeutic response by using spatially resolved technologies reveals the region‐specific ligand‐receptor interactions driving therapeutic response and the cellular architecture that correlates with response. A few examples of spatial correlates of therapeutic response are given. Tumors sensitive to ICB are often associated with the presence of TLS, increased TILs, with elevation of T cell populations such as TCF7 + CD8 + T cells and GZMB + CD8 + T cells. An oncofetal niche consisting of POSTN + CAFs, FOLR2 + TAMs and PLVAP + endothelial cells has been identified to be associated with better response to combination immunotherapy in HCC. The spatial analysis of ICB resistant tumors from multiple cancer types has identified CAF subtypes forming physical barriers, which prevent the infiltration of immune cells into the tumor. ICB, immune checkpoint blockade, TLS, Tertiary Lymphoid Structure, TILs, Tumor‐infiltrating lymphocytes.

Article Snippet: Visium and Visium HD (10× Genomics) are sequencing‐based whole‐transcriptomic approaches, with Visium achieving 55 μM resolution covering 8–20 cells, and Visium HD with 2 μm single‐cell resolution., Spatially enhanced resolution omics sequencing (Stereo‐seq), commercialised as STOmics (BGI Group), uses chips with DNA nanoballs (DNBs) containing unique coordinate identity (CID), barcodes (UMI) and poly‐T oligonucleotides.

Techniques: Clinical Proteomics

AI‐Enabled Multi‐omics for Cancer Translational and Clinical Research. AI‐driven integration of different modalities, including (i) histology images (H&E/IHC whole‐slide images), (ii) spatial omics (spatial transcriptomics, spatial proteomics), and (iii) clinical metadata (treatment response and survival data) are jointly modelled with integrative analysis (IA), artificial intelligence (AI), machine learning (ML), and deep learning (DL). Central models learn representations across modalities to support downstream spatial analyses, including reconstruction of cellular landscapes, inference of spatially defined ligand–receptor interactions, cellular neighbourhood (CN) profiling, and trajectory/pseudotime analysis. Insights generalise to biological and clinical applications such as cancer detection, biomarker prediction, survival analysis, cell‐type clustering, tumor‐microenvironment (TME) studies, and personalised treatment selection. The bottom timeline shows the evolution of deep learning approaches.

Journal: Clinical & Translational Immunology

Article Title: Spatial omics for profiling the dynamic tumor microenvironment

doi: 10.1002/cti2.70084

Figure Lengend Snippet: AI‐Enabled Multi‐omics for Cancer Translational and Clinical Research. AI‐driven integration of different modalities, including (i) histology images (H&E/IHC whole‐slide images), (ii) spatial omics (spatial transcriptomics, spatial proteomics), and (iii) clinical metadata (treatment response and survival data) are jointly modelled with integrative analysis (IA), artificial intelligence (AI), machine learning (ML), and deep learning (DL). Central models learn representations across modalities to support downstream spatial analyses, including reconstruction of cellular landscapes, inference of spatially defined ligand–receptor interactions, cellular neighbourhood (CN) profiling, and trajectory/pseudotime analysis. Insights generalise to biological and clinical applications such as cancer detection, biomarker prediction, survival analysis, cell‐type clustering, tumor‐microenvironment (TME) studies, and personalised treatment selection. The bottom timeline shows the evolution of deep learning approaches.

Article Snippet: Visium and Visium HD (10× Genomics) are sequencing‐based whole‐transcriptomic approaches, with Visium achieving 55 μM resolution covering 8–20 cells, and Visium HD with 2 μm single‐cell resolution., Spatially enhanced resolution omics sequencing (Stereo‐seq), commercialised as STOmics (BGI Group), uses chips with DNA nanoballs (DNBs) containing unique coordinate identity (CID), barcodes (UMI) and poly‐T oligonucleotides.

Techniques: Biomarker Discovery, Spatial Transcriptomics, Spatial Proteomics, Selection